The Valentines Trial: Results of the First One Week Worldwide Multicentre Enrolment Trial, Evaluating the Real World Usage of the Second Generation DIOR Paclitaxel Drug-Eluting Balloon for In-Stent Restenosis Treatment

EuroIntervention - France
doi 10.4244/eijv7i6a113
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Europa Digital & Publishing

Related search

Optical Coherence Tomography Predictors for Recurrent Restenosis After Paclitaxel-Coated Balloon Angioplasty for Drug-Eluting Stent Restenosis

Circulation Journal
MedicineCardiovascular MedicineCardiology
2018English

Stent Optimization Using Adjunctive Balloon Dilatation in the Era of Second-Generation Drug-Eluting Stents

Korean Circulation Journal
Internal MedicineCardiovascular MedicineCardiology
2017English

Angiographic Patterns of Restenosis With 2nd Generation Drug-Eluting Stent

International Heart Journal
MedicineCardiovascular MedicineCardiology
2015English

Drug-Eluting Stent Restenosis Rates?

Circulation
Cardiovascular MedicinePhysiologyCardiology
2004English

Cost-Effectiveness of Gamma Radiation for Treatment of In-Stent Restenosis: Results From the Gamma-1 Trial

Circulation
Cardiovascular MedicinePhysiologyCardiology
2002English

Comparison of Clinical Outcomes After Drug-Eluting Balloon and Drug-Eluting Stent Use for In-Stent Restenosis Related Acute Myocardial Infarction: A Retrospective Study

PeerJ
GeneticsMolecular BiologyBiochemistryBiological SciencesMedicineAgriculturalNeuroscience
2018English

Network Meta-Analysis of Balloon Angioplasty, Nondrug Metal Stent, Drug-Eluting Balloon, and Drug-Eluting Stent for Treatment of Infrapopliteal Artery Occlusive Disease

Diagnostic and Interventional Radiology
Nuclear MedicineRadiologyCardiovascular MedicineImagingCardiology
2016English

Is the Sirolimus Encapsulated Balloon a Reliable Tool for Treating the In-Stent Restenosis?—insights From the SABRE Trial

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2018English

Clinical Outcome Following Second-Generation Drug-Eluting Stent Use for Off-Label Versus On-Label Indications: Insights From the Two-Year Outcome of the TWENTE Trial

EuroIntervention
MedicineCardiovascular MedicineCardiology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy